Zoetis Inc. $ZTS Stock Holdings Lowered by Raiffeisen Bank International AG

Raiffeisen Bank International AG cut its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 78.8% in the 2nd quarter, Holdings Channel reports. The firm owned 52,336 shares of the company’s stock after selling 194,968 shares during the period. Raiffeisen Bank International AG’s holdings in Zoetis were worth $3,834,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. J. Stern & Co. LLP lifted its position in shares of Zoetis by 12,431.2% during the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock valued at $3,028,423,000 after acquiring an additional 23,877,416 shares during the last quarter. Norges Bank acquired a new position in shares of Zoetis in the 4th quarter worth $734,425,000. Flossbach Von Storch SE acquired a new position in shares of Zoetis in the 2nd quarter worth $302,601,000. BlackRock Inc. raised its position in shares of Zoetis by 10.8% during the second quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock worth $2,833,453,000 after purchasing an additional 3,845,869 shares during the period. Finally, Ruane Cunniff & Goldfarb L.P. acquired a new stake in shares of Zoetis during the first quarter worth $286,660,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of Zoetis stock opened at $75.70 on Friday. Zoetis Inc. has a 12 month low of $71.00 and a 12 month high of $155.15. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. The stock has a market cap of $31.28 billion, a PE ratio of 12.47, a price-to-earnings-growth ratio of 1.78 and a beta of 0.73. The business has a fifty day simple moving average of $75.53 and a 200-day simple moving average of $93.85.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.02. The firm had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.Zoetis’s quarterly revenue was down .2% on a year-over-year basis. During the same period in the previous year, the firm earned $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, sell-side analysts anticipate that Zoetis Inc. will post 6.2 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. Zacks Research lowered Zoetis from a “hold” rating to a “strong sell” rating in a research report on Monday, August 10th. William Blair restated a “market perform” rating on shares of Zoetis in a report on Thursday, August 6th. Cantor Fitzgerald set a $94.00 price objective on shares of Zoetis in a research note on Tuesday, August 25th. Citigroup decreased their target price on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a report on Tuesday, August 11th. Finally, Morgan Stanley set a $85.00 target price on shares of Zoetis in a research report on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $107.43.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.